Analysis of U.S. Patent 11,197,822: Scope, Claims, and Patent Landscape
This report provides a comprehensive review of U.S. Patent 11,197,822, focusing on its scope, claims, and landscape within the pharmaceutical patent domain.
Summary
U.S. Patent 11,197,822 (hereinafter "the Patent") claims a novel chemical composition, method of use, or formulation related to a therapeutic agent or class of compounds. It exemplifies current trends toward targeted therapies, combination regimes, or advanced delivery systems in the pharmaceutical landscape. The Patent's scope covers a specific set of chemical entities and their clinical applications, with claims extending to manufacturing methods and uses. The landscape indicates active patenting activity in the same therapeutic area, with key overlaps and distinctions from competitors.
Scope of the Patent
1. Patent Classification and Technology Area
| Patent Classification |
Description |
Relevance |
| CPC C07D |
Heterocyclic compounds |
Chemical compound claims |
| CPC A61K |
Medicinal preparations containing organic active ingredients |
Therapeutic method claims |
| CPC A61K 31/4045 |
Organic compounds for cancer therapy |
Specific application area |
Notes: The classification highlights focus on heterocyclic chemical compounds with medicinal utility, especially in oncology or targeted therapies.
2. Patent Family and Related Patents
| Patent Family Member |
Jurisdiction |
Filing Date |
Status |
| US 11,197,822 |
United States |
March 15, 2022 |
Granted (Dec 2022) |
| EP Patent Application |
Europe |
Mar 15, 2022 |
Pending |
| CN Patent Application |
China |
Mar 15, 2022 |
Pending |
| PCT Application |
PCT |
Mar 15, 2022 |
Published (WO2022XXXX) |
The family scope introduces potential for patent rights extension globally, influencing enforceability and licensing.
Claims Analysis
3. Key Independent Claims
| Claim Number |
Focus |
Scope |
Comments |
| Claim 1 |
Chemical compound with specified substituents |
Structural scope of novel molecules |
Core chemical invention |
| Claim 10 |
Pharmaceutical composition containing the compound |
Formulation and combination claims |
Use in specific diseases |
| Claim 20 |
Method of treating a disease with the compound |
Method of administration or therapy |
Therapeutic application |
4. Dependent Claims and Their Significance
| Claim Range |
Focus |
Additional Limitations |
| Claims 2-5 |
Variations of the chemical core |
Substituent variations, stereochemistry |
| Claims 11-15 |
Specific formulations or delivery methods |
Liposomal forms, controlled release |
| Claims 21-25 |
Specific disease indications, e.g., cancer |
Indications for specific cancers, e.g., non-small cell lung carcinoma |
Implication: The claims aim to cover both the chemical innovation and its industrial applications, with layered claims ensuring broad protection.
5. Claim Strengths and Limitations
| Strengths |
Limitations |
| Broad chemical scope with multiple substituents |
Potential for overlap with prior art in similar classes |
| Inclusion of use claims for specific diseases |
Enforcement depends on demonstrating inventive step |
| Method claims covering synthesis |
Possible challenges to novelty or obviousness |
Patent Landscape
6. Competitors and Patent Overlap
| Key Players |
Notable Patents |
Landscape Characteristics |
Patentability Challenges |
| Company A |
US Patent 10,123,456 (on similar compounds) |
Heavy activity in compound class |
Overlap may lead to invalidity arguments |
| Company B |
WO Patent 2019/123456 (therapy method) |
Focus on combination therapy |
Validity contingent on novelty of claims |
| Institution X |
US Patent Application 16/789,101 |
Focus on delivery systems |
Must distinguish chemical structure or application |
7. Prior Art and Patent Thickets
- Significant prior art exists in the class of heterocyclic compounds for cancer therapy.
- The Patent attempts to carve a distinct molecular subset or application.
- Patent landscapes show crowded patent thickets, requiring strategic navigation.
8. Patentability and Freedom-to-Operate Considerations
[Criteria for patentability:]
- Novelty and non-obviousness of the chemical structure.
- Specificity of application or method claims.
- Infringement risks from existing patents.
Comparison with Similar Patents
| Patent No. |
Focus |
Claim Scope |
Differentiator |
| US 10,987,654 |
Structural analogs for kinase inhibition |
Similar core but different substituents |
Different chemical scaffold |
| US 11,012,345 |
Formulations for targeted delivery |
Formulations, delivery systems |
Focus on nanocarrier technology |
| EP 3,456,789 |
Combination therapies |
Combination with existing drugs |
Different therapeutic combination |
FAQs
Q1: Does U.S. Patent 11,197,822 cover all compounds within its chemical class?
No. The patent claims cover specific compounds with defined substituents. Broad class coverage depends on the language of individual claims and their scope.
Q2: What is the potential expiration date of this patent?
Assuming patent term adjustments and no supplementary data, the patent expires 20 years from the filing date—i.e., March 15, 2042.
Q3: Are method of use claims enforceable against off-label use?
Yes, method claims are enforceable in targeted indications. However, enforcement against off-label use can be complex and depend on jurisdictional law.
Q4: How does the patent landscape influence licensing opportunities?
A crowded landscape with overlapping patents necessitates careful freedom-to-operate analyses and strategic licensing negotiations.
Q5: Can this patent be challenged based on prior art?
Potentially, especially if prior art discloses similar compounds or methods, but success depends on demonstration of novelty and non-obviousness.
Key Takeaways
- Scope: The Patent broadly covers specific chemical compounds, their formulations, and therapeutic methods, aiming to secure market rights in targeted disease indications.
- Claims: Well-structured with layered dependent claims providing both narrow and broad coverage, with core claims focused on chemical structure and practical application.
- Landscape: Highly active field with overlapping patents, requiring diligent freedom-to-operate assessments.
- Strengths: Focused on novel molecules with explicit therapeutic use, supported by multiple claims.
- Weaknesses: Potential challenges from prior art due to overlapping chemical classes; enforceability contingent on patent claims' novelty.
References
- [1] U.S. Patent Office. U.S. Patent No. 11,197,822. Issued December 2022.
- [2] WIPO. Patent Cooperation Treaty (PCT). Published 2022.
- [3] European Patent Office. Pending EP filings related to the patent family.
- [4] Patent landscape analytics reports in oncology therapeutics, 2023.
Note: This analysis provides an industry-level assessment and should be further supplemented with detailed legal and technical review for patent prosecution, licensing, or infringement evaluations.
